GlassScriptPhysician profile
Colette B Gordon
NPI 1447266176
$16,345.59
in general payments reported to CMS, 2019-2025
44 companies · $810 in 2025
The $810 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,851 · 2020: $2,611 · 2021: $2,717 · 2022: $3,425 · 2023: $1,943 · 2024: $1,988 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,798.30 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,699.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,412.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,272.81 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $1,223.30 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.84 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $1,026.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $929.79 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $716.95 | 2019-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $527.08 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $465.21 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $464.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $416.89 | 2019-2024 | |
| Abbvie INC. | $409.95 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $390.42 | 2019-2023 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colette Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.